

This document is intended to provide health care providers with approaches for individuals who have received COVID-19 vaccination outside of Canada. The WHO list of EUA qualified COVID-19 vaccines will be updated over time as additional COVID-19 vaccines receive emergency use listing, and as such, this document will be updated accordingly. More information on COVID-19 vaccines listed for emergency use can be found on the [WHO website](#), under the tab “Status of COVID-19 vaccines within WHO EUL/PQ evaluation process.”

Manufacturer	Name of Vaccine	Type of vaccine ¹	WHO EUA qualified	Approved schedule ^{2, 3}	Second dose options for completion of series in BC ⁴
Pfizer-BioNTech	BNT162b2 / COMIRNATY / Tozinameran (INN)	mRNA	✓	Two doses, 21-28 days apart	- Pfizer-BioNTech - Moderna
Moderna	mRNA-1273	mRNA	✓	Two doses, 28 days apart	- Moderna - Pfizer-BioNTech
AstraZeneca	AZD1222 Vaxzevria	Adenovirus (CHAdOx1) vector	✓	Two doses, 4-12 weeks apart	- AstraZeneca - COVISHIELD - Pfizer-BioNTech - Moderna
Serum Institute of India	COVISHIELD	Adenovirus (CHAdOx1) vector	✓	Two doses, 4-12 weeks apart	- AstraZeneca - COVISHIELD - Pfizer-BioNTech - Moderna
Janssen (Johnson & Johnson)	Ad26.COV2.5	Adenovirus type 26 vector	✓	One dose	N/A – one dose series
SinoPharm / Beijing Institute of Biological Products (BIBP)	Covilo / BBIBP-CorV	Whole inactivated Coronavirus	✓	Two doses, 21-28 days apart	- Pfizer-BioNTech - Moderna
Sinovac	CoronaVac	Whole inactivated Coronavirus	✓	Two doses, 14-28 days apart	- Pfizer-BioNTech - Moderna
The Gamaleya National Center	Sputnik V	Human adenovirus vector	pending		
SinoPharm / Wuhan Institute of Biological Products (WIBP)	Inactivated SARS-CoV-2 Vaccine (Vero Cell)	Whole inactivated Coronavirus	pending		
CanSinoBio	Ad5-nCoV	Adenovirus Type 5 vector	pending		
Novavax	NVX-CoV2373 / Covovax	Protein subunit	pending		
CureVac	CVnCoV/CV07050101 Zorecimeran (INN)	mRNA	pending		
Bharat Biotech, India	COVAXIN	Whole inactivated Coronavirus	pending		

¹ Types of vaccine are:

- mRNA: Pfizer, Moderna
- Adenovirus (ChAdOx) vector: AstraZeneca, COVISHIELD *
- Whole inactivated Coronavirus: Sinopharm, Sinovac, Covaxin
- Protein subunit: Novavax

* The other adenovirus-based vaccines (i.e., Janssen, Sputnik, CanSinoBio) use different vectors and so are not immunologically the same as either the AstraZeneca or COVISHIELD adenovirus vector vaccines.

² Individuals who have received a complete series with a vaccine that is WHO EUA qualified are considered fully vaccinated and no further doses are required. However, one additional dose of a COVID-19 mRNA vaccine may be provided for individuals upon request if they have been vaccinated with a WHO-approved vaccine series that is not authorized in Canada. The minimum interval between the preceding dose and the additional dose is 4 weeks.

³ Individuals who have received a series with a vaccine that is not WHO EUA qualified should be offered a full COVID-19 vaccine series using a vaccine available in BC. There is no minimum interval required when restarting the series following receipt of a non-WHO approved vaccine.

⁴ Individuals who have received a first dose of a COVID-19 vaccine overseas that is also available in BC should receive the same vaccine for their second dose if readily available, and if they meet the current BC eligibility criteria for 2nd dose (i.e., at least 4 weeks following first dose). If the vaccine they received for their first dose is not available in BC, but the **same type of vaccine** is available, this should be offered. A 6-8 week interval between doses is recommended. A minimum interval of 4 weeks is acceptable, if required.